olezarsen (Ionis-APOCIII-LRx) / Ionis, Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
olezarsen (Ionis-APOCIII-LRx) / Ionis
2021-003280-95: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS) Estudio abierto de prolongación de AKCEA-APOCIII-LRx administrado a pacientes con síndrome de quilomicronemia familiar (SQF)

Not yet recruiting
3
60
Europe
ISIS 678354, ISIS 678354, Solution for injection
Ionis Pharmaceuticals, Inc., IONIS PHARMACEUTICALS, INC., Ionis
Familial Chylomicronemia Syndrome (FCS) Síndrome de quilomicronemia familiar (SQF), Patients with hypertriglyceridemia Pacientes con hipertrigliceridemia, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
BALANCE, NCT04568434: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Completed
3
66
Europe, Canada, US, RoW
Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo
Ionis Pharmaceuticals, Inc., Akcea Therapeutics
Familial Chylomicronemia Syndrome
07/23
10/23
2020-002536-67: A Study of AKCEA-APOCIIILRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Not yet recruiting
3
60
Europe
ISIS 678354, ISIS 678354, Solution for injection
Ionis Pharmaceuticals, Inc., IONIS PHARMACEUTICALS, INC., Ionis
Familial Chylomicronemia Syndrome (FCS), Patients with hypertriglyceridemia, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05079919 / 2021-002192-19: A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Active, not recruiting
3
617
Europe, Canada, US, RoW
Olezarsen, AKCEA-APOCIII-LRx, ISIS 678354, Placebo
Ionis Pharmaceuticals, Inc.
Severe Hypertriglyceridemia
04/25
07/25
NCT05130450: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
60
Europe, Canada, US
Olezarsen, ISIS 678354, AKCEA -APOCIII-LRx
Ionis Pharmaceuticals, Inc.
Familial Chylomicronemia Syndrome
01/25
04/25
NCT05185843 / 2021-003635-29: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Active, not recruiting
3
24
Europe, Canada, US
Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx
Ionis Pharmaceuticals, Inc.
Familial Chylomicronemia Syndrome
03/25
06/25
NCT05610280: A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Active, not recruiting
3
1478
Europe, Canada, US, RoW
Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo
Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
03/25
06/25
NCT05552326: A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Active, not recruiting
3
446
Europe, Canada, US, RoW
Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo
Ionis Pharmaceuticals, Inc.
Severe Hypertriglyceridemia
06/25
07/25
NCT05681351: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Recruiting
3
700
Europe, Canada, US, RoW
Olezarsen, AKCEA-APOCIII-LRx, ISIS 678354
Ionis Pharmaceuticals, Inc.
Severe Hypertriglyceridemia
05/26
09/26

Download Options